U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C24H26N4O5S
Molecular Weight 482.552
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AMENAMEVIR

SMILES

CC1=CC=CC(C)=C1N(CC(=O)NC2=CC=C(C=C2)C3=NOC=N3)C(=O)C4CCS(=O)(=O)CC4

InChI

InChIKey=MNHNIVNAFBSLLX-UHFFFAOYSA-N
InChI=1S/C24H26N4O5S/c1-16-4-3-5-17(2)22(16)28(24(30)19-10-12-34(31,32)13-11-19)14-21(29)26-20-8-6-18(7-9-20)23-25-15-33-27-23/h3-9,15,19H,10-14H2,1-2H3,(H,26,29)

HIDE SMILES / InChI

Molecular Formula C24H26N4O5S
Molecular Weight 482.552
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Amenamevir is an antiviral agent discovered by Astellas Pharma Inc. and is considered to exert anantiviral effect by inhibiting the activity of the helicase-primase complex, which is involved in DNA replication of herpes virus. It is a helicase-primase inhibitor against herpes simplex virus 1 (HSV-1), HSV-2, and varicella zoster virus. Amenamevir inhibited the in vitro replication of HSV-1 with a mean 50% effective concentration (EC(50)) of 14 ng/ml. Amenamevir was approved in Japan for the treatment of Herpes zoster.

Approval Year

PubMed

PubMed

TitleDatePubMed
Efficacy of herpes virus helicase-primase inhibitor, ASP2151, for treating herpes simplex keratitis in mouse model.
2013 Apr

Sample Use Guides

In Vivo Use Guide
Herpes zoster: The usual adult dosage is 400 mg of amenamevir administered orally once daily after a meal
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: Amenamevir inhibits the replication of the HSV strains isolated in Japan and the United States as well as the laboratory-stocked strains. The mean EC50s of Amenamevir against HSV-1 and HSV-2 are 14 (range, 7.7 to 20) and 30 ng/mL (range, 15 to 58), respectively. https://www.ncbi.nlm.nih.gov/pubmed/23274658
Amenamevir inhibited the DNA-dependent ATPase activity of the HSV-1 helicase-primase complex within the concentration range from 0.0001 to 3 umol/L in a concentration-dependent manner, and the 50% inhibitory concentration (IC50) was 0.078 umol/L.
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:21:30 GMT 2023
Edited
by admin
on Sat Dec 16 16:21:30 GMT 2023
Record UNII
94X46KW4AE
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AMENAMEVIR
INN  
INN  
Official Name English
ASP2151
Code English
Amenamevir [WHO-DD]
Common Name English
amenamevir [INN]
Common Name English
N-(2,6-DIMETHYLPHENYL)-N-(2-((4-(1,2,4-OXADIAZOL-3-YL)PHENYL)AMINO)-2-OXOETHYL)-1,1-DIOXOTHIANE-4-CARBOXAMIDE
Systematic Name English
ASP-2151
Code English
AMENAMEVIR [JAN]
Common Name English
AMENAMEVIR [MI]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C281
Created by admin on Sat Dec 16 16:21:30 GMT 2023 , Edited by admin on Sat Dec 16 16:21:30 GMT 2023
Code System Code Type Description
PUBCHEM
11397521
Created by admin on Sat Dec 16 16:21:30 GMT 2023 , Edited by admin on Sat Dec 16 16:21:30 GMT 2023
PRIMARY
INN
9054
Created by admin on Sat Dec 16 16:21:30 GMT 2023 , Edited by admin on Sat Dec 16 16:21:30 GMT 2023
PRIMARY
SMS_ID
100000175542
Created by admin on Sat Dec 16 16:21:30 GMT 2023 , Edited by admin on Sat Dec 16 16:21:30 GMT 2023
PRIMARY
NCI_THESAURUS
C90782
Created by admin on Sat Dec 16 16:21:30 GMT 2023 , Edited by admin on Sat Dec 16 16:21:30 GMT 2023
PRIMARY
WIKIPEDIA
Amenamevir
Created by admin on Sat Dec 16 16:21:30 GMT 2023 , Edited by admin on Sat Dec 16 16:21:30 GMT 2023
PRIMARY
EPA CompTox
DTXSID101027753
Created by admin on Sat Dec 16 16:21:30 GMT 2023 , Edited by admin on Sat Dec 16 16:21:30 GMT 2023
PRIMARY
FDA UNII
94X46KW4AE
Created by admin on Sat Dec 16 16:21:30 GMT 2023 , Edited by admin on Sat Dec 16 16:21:30 GMT 2023
PRIMARY
MERCK INDEX
m12086
Created by admin on Sat Dec 16 16:21:30 GMT 2023 , Edited by admin on Sat Dec 16 16:21:30 GMT 2023
PRIMARY
CAS
841301-32-4
Created by admin on Sat Dec 16 16:21:30 GMT 2023 , Edited by admin on Sat Dec 16 16:21:30 GMT 2023
PRIMARY
DRUG BANK
DB11701
Created by admin on Sat Dec 16 16:21:30 GMT 2023 , Edited by admin on Sat Dec 16 16:21:30 GMT 2023
PRIMARY
DRUG CENTRAL
5266
Created by admin on Sat Dec 16 16:21:30 GMT 2023 , Edited by admin on Sat Dec 16 16:21:30 GMT 2023
PRIMARY
Related Record Type Details
TARGET ORGANISM->INHIBITOR
Related Record Type Details
ACTIVE MOIETY